Viewing Study NCT06061718


Ignite Creation Date: 2025-12-25 @ 4:58 AM
Ignite Modification Date: 2025-12-26 @ 3:58 AM
Study NCT ID: NCT06061718
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-03
First Post: 2023-09-25
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Sponsor: Glaukos Corporation
Organization:

Study Overview

Official Title: Multicenter, Open-label, Single-arm Trial to Evaluate the Safety and Efficacy of iDoseĀ® TR (Travoprost Intraocular Implant) in Conjunction With Cataract Surgery
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: